Neuromelanin (NM) MRI has received increasing interest in applications to diagnosis of Parkinson’s disease. A reduction of T1 associated with paramagnetic melanin-iron complexes is assumed to be the primary contrast mechanism. NM is able to chelate large quantities of iron but also, to a lesser extent, other transition metals, in particular copper. Here, we investigated the effect of different copper/iron concentrations bound to NM on water T1 and T2. Our results corroborate previous studies suggesting a concentration-dependent decrease of T1 for iron-loaded melanin. Additionally, we found a synergetic effect if both metals are simultaneously present leading to a pronounced T1-shortening.
(1) Sulzer D., Cassidy C., Horga G., Kang U.J., Fahn S., Casella L., Pezzoli G., Langley J., Hu XP, Zucca F.A., Isaias IU and Zecca L. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. NPJ Parkinsons Dis. 2018 Apr 10;4:11.
(2) Möller, H.E., Bossoni, L., Connor, J.R., Crichton, R.R., Does, M.D., Ward, R.J., Zecca, L., Zucca, F.A., and Ronen, I. (2019). Iron, myelin, and the brain: Neuroimaging meets neurobiology. Trends Neurosci 42, 384–401.
(3) Brammerloh, M., Morawski, M., Weigelt, I., Reinert, T., Lange, C., Pelicon, P., Vavpetič, P., Jankuhn, J., Jäger, C., Alkemade, A., Balesar, R., Pine, K., Gavriilidis, F., Trampel, R., Reimer, E., Arendt, T., Weiskopf, N., and Kirilina,E. (2020). Toward an early diagnostic marker of Parkinson’s: measuring iron in dopaminergic neurons with MR relaxometry. bioRxiv; doi: https://doi.org/10.1101/2020.07.01.170563
(4) Priovoulos, N., van Boxel, S. C. J., Jacobs, H. I. L., Poser, B. A., Uludag, K., Verhey, F. R. J., and Ivanov, D. (2020). Brain Struct Funct 225, 2757–2774.
(5) Zucca, F. A., Bellei, C., Giannelli, S., Terreni, M. R., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., and Zecca, L. (2006). J Neural Transm 113, 757–67.
(6) Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., Karatekin, E., Kleinman, M. H., Turro, N., Hornykiewicz, O., and Zucca,F. A. (2004). PNAS 101, 9843–9848.
(7) Trujillo P., Summers P.E., Ferrari E., Zucca F.A., Sturini M., Mainardi L.T., Cerutti S., Smith A.K., Smith S.A., Zecca L., Costa A. MRM 2017;78(5):1790-1800.
(8) Ferrari E. ,Capucciati A., Prada I., Zucca FA., D’Arrigo G., Pontiroli D., Bridelli MG., Sturini M., Bubacco L., Monzani E., Verderio C., Zecca .L, and Casella L. ACS Chem. Neurosci. 2017, 8(3), 501-512
(9) Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L. and Zecca, L. (2014). Neuromelanin of the Human Substantia Nigra: An Update. Neurotoxicity Research 25, 13–23.